Research peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Initially stating that he "sees nobody deserving" to replace him as the next president, Duterte in August 2021 announced he would run for vice president in the upcoming 2022 national elections, drawing suspicions from critics that he would extend his term. Duterte's political party, the PDP–Laban Cusi faction, named its standard bearer: former Philippine National Police chief and Senator Ronald dela Rosa, who was widely suspected to be a placeholder for Duterte's daughter, Davao City mayor Sara. Duterte later withdrew his candidacy, announced his retirement from politics, and had his long-time aide, Senator Bong Go, substitute him. Despite polls showing she was the preferred candidate for presidency, Sara decided to settle for the vice presidential race. This prompted dela Rosa to withdraw his candidacy, which Go would later fill in. Sara's move had Duterte dismayed and he initially retracted his planned retirement, announcing he would run for vice president. Ultimately, he decided not to face his daughter, endorsed a Go–Sara tandem, and declared his intent on running as Senator. However, Sara decided to run in tandem with Bongbong Marcos, who announced his presidential candidacy. Stating his heart and mind contradicted his actions, Go later withdrew his presidential candidacy; shortly after, Duterte officially withdrew his senate bid.
In August 2026, Disney and TikTok announced a content-sharing partnership that will allow participating TikTok creators to use approved material from Disney films and television programs in their videos. Selected creator videos will also be featured within Disney+ through its Verts mobile video section. The initiative includes content related to Disney properties such as Marvel, Star Wars, Pixar, and FX, and is expected to begin as a pilot in the United States before potentially expanding to other markets.
=== Category:EC 3.4 (act on peptide bonds - Peptidase) === Category:EC 3.4.11 Alanine aminopeptidase Category:EC 3.4.15 Angiotensin converting enzyme Category:EC 3.4.21 Serine protease Chymotrypsin (EC 3.4.21.1) Trypsin (EC 3.4.21.4) Thrombin (EC 3.4.21.5) Factor X (EC 3.4.21.6) Plasmin (EC 3.4.21.7) Acrosin (EC 3.4.21.10) Factor VII (EC 3.4.21.21) Factor IX (EC 3.4.21.22) Prolyl oligopeptidase (EC 3.4.21.26) Factor XI (EC 3.4.21.27) Elastase (EC 3.4.21.37) Factor XII (EC 3.4.21.38) Proteinase K (EC 3.4.21.64) Tissue plasminogen activator (EC 3.4.21.68) Protein C (EC 3.4.21.69) Category:EC 3.4.22 Separase (EC 3.4.22.49) Category:EC 3.4.23 Pepsin (EC 3.4.23.1) Rennet (EC 3.4.23.4) Renin (EC 3.4.23.15) Trypsinogen (EC 3.4.23.18) and (20/21/23/24/26) Plasmepsin (EC 3.4.23.39) Category:EC 3.4.24 Matrix metalloproteinase (EC 3.4.24.7) Category:EC 3.4.25 Metalloendopeptidase
On 8 February 2022, Aníbal Torres was appointed as Prime Minister of Peru. Torres had previously served as the Minister of Justice. The appointment of President Pedro Castillo's fourth cabinet came in the context of an attempt to resolve a political crisis.
Sources: en.wikipedia.org
=== Cough === Codeine is used to relieve coughing. Evidence does not support its use for acute cough suppression in children. In Europe, it is not recommended as a cough medicine for those under 12 years of age. Some tentative evidence shows it can reduce a chronic cough in adults.
== Research == Blisibimod, an inhibitor of both soluble and membrane-bound BAFF, has demonstrated similar reductions of B cells in clinical trials and is being investigated in a Phase II clinical study for patients with lupus. BR3-Fc, a recombinant fusion protein built with the extracellular ligand-binding portion of BAFF-R, blocks activation of this receptor by BLyS and is in early-stage pharmaceutical development. Rituximab, an anti-CD20 monoclonal antibody, has been approved for some indications. Ocrelizumab, ofatumumab, and "third-generation" anti-CD20 monoclonals are in development. Other drugs addressing B lymphocyte hyperactivity include atacicept, a recombinant fusion protein that is built with the extracellular ligand binding portion of TACI and blocks activation of TACI by APRIL and BLyS. It failed a Phase II trial for multiple sclerosis.
== Synthesis and structure == With the formula Zn[(S2P(OR)2]2, zinc dithiophosphate features diverse R groups. Typically, R is a branched or linear alkyl between 1-14 carbons in length. Examples include 2-butyl, pentyl, hexyl, 1,3-dimethylbutyl, heptyl, octyl, isooctyl (2-ethylhexyl), 6-methylheptyl, 1-methylpropyl, dodecylphenyl, and others. A list of examples with their CAS numbers is here. Zinc dithiophosphate are often produced in two steps. First phosphorus pentasulfide is heated with suitable alcohols (ROH) to give the dithiophosphoric acid. A wide variety of alcohols can be employed, which allows the lipophilicity of the final zinc product to be fine tuned. The resulting dithiophosphoric acid is then neutralized, e.g., with ammonia or by adding zinc oxide:
On 22 December 1988, the Brazzaville Protocol was enshrined in the Tripartite Accord, which required the SADF to withdraw from Angola and reduce its troop levels in South West Africa to a token force of 1,500 within twelve weeks. Simultaneously, all Cuban brigades would be withdrawn from the border to an area north of the 15th parallel. At least 3,000 Cuban military personnel would depart Angola by April 1989, with another 25,000 leaving within the next six months. The remaining troops would depart at a date not later than 1 July 1991. An additional condition was that South Africa would cease all support for UNITA, and Angola likewise for PLAN and MK. On 20 December 1988, United Nations Security Council Resolution 626 was passed, creating the United Nations Angola Verification Mission (UNAVEM) to verify the redeployment northwards and subsequent withdrawal of the Cuban forces from Angola. UNAVEM included observers from Western as well as non-aligned and communist nations. In February 1989 the United Nations Transition Assistance Group (UNTAG) was formed to monitor the South West African peace process.
=== Passive targeting === Passive targeting is achieved by incorporating the therapeutic agent into a macromolecule or nanoparticle that passively reaches the target organ. In passive targeting, the drug's success is directly related to circulation time. This is achieved by cloaking the nanoparticle with some sort of coating. Several substances can achieve this, with one of them being polyethylene glycol (PEG). By adding PEG to the surface of the nanoparticle, it is rendered hydrophilic, thus allowing water molecules to bind to the oxygen molecules on PEG via hydrogen bonding. The result of this bond is a film of hydration around the nanoparticle which makes the substance antiphagocytic. The particles obtain this property due to the hydrophobic interactions that are natural to the reticuloendothelial system (RES), thus the drug-loaded nanoparticle is able to stay in circulation for a longer period of time. To work in conjunction with this mechanism of passive targeting, nanoparticles that are between 10 and 100 nanometers in size have been found to circulate systemically for longer periods of time.
Sources: en.wikipedia.org
== Awards == 2023 Tung-Ho Outstanding Research Award, THS Foundation 2023 16th Taiwan Outstanding Women in Science Awards, Wu Chien Shiung Education Foundation & L'ORÉAL Taiwan 2022 Outstanding Research Award, National Science and Technology Council 2022 Outstanding Research Award, National Science and Technology Council 2021 National Innovation Award 2020 Taiwan Society for Mass Spectrometry Medal 2011 Taiwan Society for Mass Spectrometry Outstanding Scholar Award 2007 Federation of Asian Chemical Societies Distinguished Young Chemists Award 2006 Chinese Chemical Society Outstanding Young Investigator Award
They also noticed that the game "goes about fixing a lot of the niggling complaints we had about Episode One," applauding the open forests and rocky hills. The New York Times wrote that "while it sows a few seeds for the final episode of the trilogy, the game lacks the driving force of the previous episode". GameSpy felt that it was less consistent than its predecessors, and that the opening segments were "arguably the weakest".
=== Genetic influence and environmental factors === Various studies have found direct genetic effects to account for at least 46% of the variation of timing of puberty in well-nourished populations. The genetic association of timing is strongest between mothers and daughters. The specific genes affecting timing are not yet known. Among the candidates is an androgen receptor gene. Researchers have hypothesized that early puberty onset may be caused by certain hair care products containing estrogen or placenta, and by certain chemicals, namely phthalates, which are used in many cosmetics, toys, and plastic food containers.
== Parallel evolution of cardiotonic steroid resistance in vertebrates == Several studies have detailed the evolution of cardiotonic steroid resistance of the alpha-subunit gene family of Na/K-ATPase (ATP1A) in vertebrates via amino acid substitutions most often located in the first extracellular loop domain. Amino acid substitutions conferring cardiotonic steroid resistance have evolved independently many times in all major groups of tetrapods. ATP1A1 has been duplicated in some groups of frogs and neofunctionlised duplicates carry the same cardiotonic steroid resistance substitutions (Q111R and N122D) found in mice, rats and other muroids.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.